<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220626055278N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-19</date_registration>
      <primary_sponsor>Zahedan University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of high-intensity laser on pain and disability in women with neck pain</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of High-intensity laser on pain, disability and upper trapezius muscle activity in women with cervical myofascial pain syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-07-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64413</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Other, Purpose: Treatment, Randomization description: Randomization will be done based on the quadruple permutation blocks method. All possible blocks are arranged as follows: 1:ABAB  2:AABB  3: ABBA     4: BBAA   5:BABA   6: BAAB     
We need 10 blocks to select 40 people. We randomly select these blocks from numbers 1 to 6. Using R soft ware, we choose a random number between numbers 1 to 6. For example, if number 6 is chosen as the first block and number 2 as the second block, the people who enter the study will be given BAABAABB respectively. Finally, group A: control and group B: intervention, Blinding description: Patients will be unaware of the grouping.Physiotherapy modalities are explained to the patients and they are told that one or more modalities are used in their treatment, but they will be unaware of what modalities are used in each group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Myofascial pain syndrom.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: It will include high-intensity laser and conventional physiotherapy(trans cutaneous electrical nerve stimulation, ultrasonic waves and ischemic pressure). High-intensity laser with wavelengths of 660, 800, 905, 970 nano meter and maximum power of 20 watts is made in Italy. The time of laser treatment will be five minutes and eight seconds. The total energy received by the tissue is 2957 joules, which will be applied by the physiotherapist on the upper trapezius muscle of the patient in the prone position. In this group, trans cutaneous electrical nerve stimulation with frequency of 60 Hertz and pulse duration of 100 milliseconds and tolerable intensity of 10 to 30 milliamps for 20 minutes will be applied through two electrodes that  we are placing on the upper trapezius muscle of the patient. Ultrasonic waves with frequency of 1 Mega Hertz and intensity of 1.5 watts per square centimeter and continuous current will be applied to the upper trapezius muscle for 5 minutes. Ischemic pressure will be applied 4 times, each time for 90 seconds with uniform pressure by the physiotherapist's thumb on the trigger points of the upper trapezius muscle. Trans cutaneous electrical nerve stimulation and ultrasonic waves will be performed by devices manufactured by Novin Medical Engineering company. The intervention will consist of twelve sessions, during four weeks, three times each week. Intervention 2: Control group: conventional physiotherapy will include trans cutaneous electrical nerve stimulation, ultrasonic waves and ischemic pressure. Trans cutaneous electrical nerve stimulation with frequency of 60 Hertz and pulse duration of 100 milliseconds and tolerable intensity of 10 to 30 milliamps for  20 minutes, will be applied through two electrodes that we are placing on the upper trapezius muscle of the patient. Ultrasonic waves with frequency of 1 Mega Hertz and intensity of 1.5 watts per square centimeter and continuous current will be applied to the upper trapezius muscle for 5 minutes. Ischemic pressure will be applied 4 times, each time for 90 seconds with uniform pressure by the physiotherapist's thumb on the trigger points of the upper trapezius muscle. Trans cutaneous electrical nerve stimulation and ultrasonic waves will be performed by devices manufactured by Novin Medical Engineering company.                                                                          The intervention will consist of twelve sessions, during four weeks, three times each week.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Sargolzehi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.35 , East Azadegan St., Corner of Farhad St</address>
        <city>Zahedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9817687643</zip>
        <telephone>+98 54 3321 7006</telephone>
        <email>Sargolzaei_pt@yahoo.com</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hassan Namvar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Modares St., next to medical imaging, Namvaran Doctors Building, Atieh Physiotherapy</address>
        <city>Zahedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9816677389</zip>
        <telephone>+98 54 3344 6819</telephone>
        <email>hassan_753@zaums.ac.ir</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>women aged 18 to 55 years
Primary complaint of neck pain with shoulder girdle symptoms
Percentage of neck disability index between 10 and 40
Visual analogue scale greater than or equal to 3
Existence of active trigger point in the upper trapezius muscle
Having five major criteria and at least one of three minor criteria based on Simon diagnostic method for clinical diagnosis of myofacial neck pain syndrome
Not having cervical spine surgery, canal stenosis at level of the cervical vertebrae, neck radicular pain, fibromyalgia</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>55 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Failure to complete treatment sessions
Exacerbation of symptoms or patient dissatisfaction with the continuation of treatment sessions</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: It will include high-intensity laser and conventional physiotherapy(trans cutaneous electrical nerve stimulation, ultrasonic waves and ischemic pressure). High-intensity laser with wavelengths of 660, 800, 905, 970 nano meter and maximum power of 20 watts is made in Italy. The time of laser treatment will be five minutes and eight seconds. The total energy received by the tissue is 2957 joules, which will be applied by the physiotherapist on the upper trapezius muscle of the patient in the prone position. In this group, trans cutaneous electrical nerve stimulation with frequency of 60 Hertz and pulse duration of 100 milliseconds and tolerable intensity of 10 to 30 milliamps for 20 minutes will be applied through two electrodes that  we are placing on the upper trapezius muscle of the patient. Ultrasonic waves with frequency of 1 Mega Hertz and intensity of 1.5 watts per square centimeter and continuous current will be applied to the upper trapezius muscle for 5 minutes. Ischemic pressure will be applied 4 times, each time for 90 seconds with uniform pressure by the physiotherapist's thumb on the trigger points of the upper trapezius muscle. Trans cutaneous electrical nerve stimulation and ultrasonic waves will be performed by devices manufactured by Novin Medical Engineering company. The intervention will consist of twelve sessions, during four weeks, three times each week.</i_keyword>
      <i_keyword>Control group: conventional physiotherapy will include trans cutaneous electrical nerve stimulation, ultrasonic waves and ischemic pressure. Trans cutaneous electrical nerve stimulation with frequency of 60 Hertz and pulse duration of 100 milliseconds and tolerable intensity of 10 to 30 milliamps for  20 minutes, will be applied through two electrodes that we are placing on the upper trapezius muscle of the patient. Ultrasonic waves with frequency of 1 Mega Hertz and intensity of 1.5 watts per square centimeter and continuous current will be applied to the upper trapezius muscle for 5 minutes. Ischemic pressure will be applied 4 times, each time for 90 seconds with uniform pressure by the physiotherapist's thumb on the trigger points of the upper trapezius muscle. Trans cutaneous electrical nerve stimulation and ultrasonic waves will be performed by devices manufactured by Novin Medical Engineering company.                                                                          The intervention will consist of twelve sessions, during four weeks, three times each week.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain that is more than 3 or 3 befor intervention, decreases after the intervention. Timepoint: Measurement befor the start of the intervention and 4 weeks after the application of the intervention. Method of measurement: Visual analoge Scale.</prim_outcome>
      <prim_outcome>Disability, befor the intervention, its percentage is between 10 and 40 and decreases after the intervention. Timepoint: Measurement befor the start of the intervention and 4 weeks after the application of the intervention. Method of measurement: Neck Disability Index Questionnaire.</prim_outcome>
      <prim_outcome>Increased muscle activity that decreases after the intervention. Timepoint: Measurement befor the start of the intervention and 4 weeks after the application of the intervention. Method of measurement: Surface Electromyography Device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zahedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-25</approval_date>
        <contact_name>Ethics committee of Zahedan University of Medical Sciences</contact_name>
        <contact_address>Dr. Hesabi Square, Imam Hossein Blvd, compus of university of medical sciences Zahedan Sistan-va-Balouchestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
